418 related articles for article (PubMed ID: 12487619)
1. Intestinal graft-versus-host disease: mechanisms and management.
Takatsuka H; Iwasaki T; Okamoto T; Kakishita E
Drugs; 2003; 63(1):1-15. PubMed ID: 12487619
[TBL] [Abstract][Full Text] [Related]
2. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
3. [Prophylaxis of acute graft-versus-host disease].
Murata M
Rinsho Ketsueki; 2015 Oct; 56(10):2144-52. PubMed ID: 26458454
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment.
Holler E
Best Pract Res Clin Haematol; 2007 Jun; 20(2):281-94. PubMed ID: 17448962
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.
Finke J; Schmoor C; Bethge WA; Ottinger H; Stelljes M; Volin L; Heim D; Bertz H; Grishina O; Socie G
Lancet Haematol; 2017 Jun; 4(6):e293-e301. PubMed ID: 28583289
[TBL] [Abstract][Full Text] [Related]
8. Current and emerging strategies for the prevention of graft-versus-host disease.
Choi SW; Reddy P
Nat Rev Clin Oncol; 2014 Sep; 11(9):536-47. PubMed ID: 24958183
[TBL] [Abstract][Full Text] [Related]
9. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD.
Jacobsohn DA; Vogelsang GB
Drugs; 2002; 62(6):879-89. PubMed ID: 11929336
[TBL] [Abstract][Full Text] [Related]
10. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.
Cooke KR; Olkiewicz K; Erickson N; Ferrara JL
J Endotoxin Res; 2002; 8(6):441-8. PubMed ID: 12697087
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
12. Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft
Rayasam A; Drobyski WR
Front Immunol; 2021; 12():779076. PubMed ID: 34899738
[TBL] [Abstract][Full Text] [Related]
13. Acute Graft-versus-Host Disease: Novel Biological Insights.
Teshima T; Reddy P; Zeiser R
Biol Blood Marrow Transplant; 2016 Jan; 22(1):11-6. PubMed ID: 26453971
[TBL] [Abstract][Full Text] [Related]
14. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
15. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
17. Management of acute graft versus host disease (GvHD).
Bacigalupo A; Palandri F
Hematol J; 2004; 5(3):189-96. PubMed ID: 15167903
[TBL] [Abstract][Full Text] [Related]
18. Comparative tolerability of treatments for inflammatory bowel disease.
Stein RB; Hanauer SB
Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
[TBL] [Abstract][Full Text] [Related]
19. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
[TBL] [Abstract][Full Text] [Related]
20. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]